WEC
ACAD icon

Winslow Evans & Crocker’s Acadia Pharmaceuticals ACAD Stock Holding History

Winslow Evans & Crocker’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-125
Closed -$6K – 1080
2020
Q2 		$6K Sell
125
-375
-75% -$18K ﹤0.01% 829
2020
Q1 		$22K Hold
500
– – 0.01% 553
2019
Q4 		$22K Buy
+500
New +$21.8K 0.01% 644
2018
Q2 		– Sell
-2,100
Closed -$47.2K – 1124
2018
Q1 		$47.2K Sell
2,100
-650
-24% -$18K 0.02% 490
2017
Q4 		$82.8K Sell
2,750
-1,050
-28% -$33.6K 0.03% 400
2017
Q3 		$143K Sell
3,800
-1,300
-25% -$42.3K 0.05% 300
2017
Q2 		$142K Hold
5,100
– – 0.04% 369
2017
Q1 		$175K Buy
5,100
+1,600
+46% +$56.5K 0.06% 314
2016
Q4 		$101K Buy
3,500
+1,100
+46% +$29.1K 0.03% 404
2016
Q3 		$76.3K Sell
2,400
-2,000
-45% -$67.8K 0.02% 455
2016
Q2 		$143K Buy
4,400
+2,400
+120% +$80.3K 0.04% 316
2016
Q1 		$55.9K Buy
2,000
+1,000
+100% +$21.8K 0.02% 473
2015
Q4 		$35.6K Hold
1,000
– – 0.01% 601
2015
Q3 		$33.1K Buy
+1,000
New +$41.6K 0.01% 588

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Winslow Evans & Crocker's ACAD Position: Q3 2020 in Review

Winslow Evans & Crocker sold out of Acadia Pharmaceuticals (ACAD) in Q3 2020, closing a stake of 125 shares — an estimated $6K sold.

Winslow Evans & Crocker first reported a position in ACAD in Q3 2015 and held it in 14 quarters. The position peaked at $175K in Q1 2017. 267 funds tracked by Wall St. Rank hold ACAD as of Q3 2020.

  • Winslow Evans & Crocker reported no remaining Acadia Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Winslow Evans & Crocker sold 125 Acadia Pharmaceuticals shares in Q3 2020, an estimated $6K.
  • Winslow Evans & Crocker first reported a position in Acadia Pharmaceuticals in Q3 2015 and held it in 14 quarters.
  • Winslow Evans & Crocker's Acadia Pharmaceuticals position peaked at $175K in Q1 2017.
  • 267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2020.

Based on Winslow Evans & Crocker's 13F filing for Q3 2020, filed 21 Oct 2020.